Your browser is no longer supported. Please, upgrade your browser.
RVNC Revance Therapeutics, Inc. daily Stock Chart
Revance Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.96 Insider Own2.50% Shs Outstand54.26M Perf Week1.58%
Market Cap1.26B Forward P/E- EPS next Y-3.53 Insider Trans0.00% Shs Float54.23M Perf Month2.65%
Income-186.10M PEG- EPS next Q-1.09 Inst Own95.68% Short Float11.90% Perf Quarter18.01%
Sales0.20M P/S6308.17 EPS this Y6.90% Inst Trans7.95% Short Ratio12.26 Perf Half Y-0.29%
Book/sh4.71 P/B5.17 EPS next Y19.50% ROA-47.20% Target Price34.60 Perf Year103.42%
Cash/sh9.54 P/C2.55 EPS next 5Y11.60% ROE-89.00% 52W Range9.88 - 27.97 Perf YTD50.15%
Dividend- P/FCF- EPS past 5Y-2.50% ROI-72.90% 52W High-12.33% Beta1.65
Dividend %- Quick Ratio10.50 Sales past 5Y1.50% Gross Margin- 52W Low148.18% ATR1.29
Employees193 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)52.37 Volatility7.59% 4.93%
OptionableYes Debt/Eq0.68 EPS Q/Q-29.20% Profit Margin- Rel Volume0.27 Prev Close24.37
ShortableYes LT Debt/Eq0.68 EarningsAug 06 AMC Payout- Avg Volume526.20K Price24.52
Recom1.90 SMA200.77% SMA502.34% SMA20023.03% Volume85,886 Change0.62%
Aug-11-20Resumed Mizuho Buy $32
Mar-23-20Downgrade Goldman Buy → Neutral $32 → $15
Dec-02-19Initiated Goldman Buy
Oct-30-19Upgrade Wells Fargo Market Perform → Outperform $20
Jun-11-19Initiated Barclays Overweight $28
Feb-15-19Initiated Wells Fargo Market Perform
Feb-14-19Initiated H.C. Wainwright Buy $25
Jan-29-19Initiated Stifel Buy $50
Nov-16-18Upgrade Guggenheim Neutral → Buy
Sep-17-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Apr-20-18Reiterated Mizuho Buy $54 → $48
Mar-27-18Initiated Needham Buy $42
Mar-05-18Initiated Goldman Buy $60
Jan-09-18Downgrade Guggenheim Buy → Neutral
Dec-06-17Reiterated Mizuho Buy $37 → $54
Dec-06-17Initiated Guggenheim Buy $42
Nov-27-17Initiated Barclays Overweight $31
Nov-17-17Initiated Mizuho Buy $37
Aug-22-17Initiated JMP Securities Mkt Outperform $34
Nov-29-16Initiated Aegis Capital Buy $28
Aug-11-20 08:30AM  
Aug-06-20 04:05PM  
Jul-30-20 04:05PM  
Jul-24-20 09:46AM  
Jul-23-20 06:20PM  
Jul-05-20 03:28PM  
Jun-30-20 04:05PM  
Jun-26-20 09:57AM  
Jun-18-20 12:27PM  
Jun-09-20 08:10PM  
Jun-04-20 04:05PM  
Jun-02-20 04:05PM  
Jun-01-20 08:30AM  
May-20-20 08:12AM  
May-19-20 08:01AM  
May-09-20 10:01PM  
May-07-20 04:05PM  
May-01-20 08:30AM  
Apr-30-20 04:05PM  
Apr-27-20 09:16AM  
Apr-21-20 08:05AM  
Apr-09-20 08:55AM  
Apr-07-20 04:05PM  
Mar-26-20 04:05PM  
Mar-25-20 08:36AM  
Mar-07-20 12:26AM  
Mar-03-20 04:05PM  
Feb-27-20 01:08PM  
Feb-25-20 04:05PM  
Feb-24-20 04:05PM  
Feb-14-20 08:00AM  
Feb-12-20 06:55AM  
Feb-10-20 04:08PM  
Feb-07-20 07:32AM  
Feb-06-20 08:00AM  
Jan-21-20 05:32AM  
Jan-19-20 09:13AM  
Jan-10-20 10:11AM  
Jan-09-20 04:05PM  
Dec-20-19 05:35PM  
Dec-05-19 08:00AM  
Dec-04-19 07:41AM  
Dec-03-19 04:01PM  
Dec-02-19 08:00AM  
Nov-25-19 08:00AM  
Nov-24-19 04:19PM  
Nov-15-19 04:29PM  
Nov-12-19 04:05PM  
Nov-06-19 04:05PM  
Nov-05-19 06:43AM  
Nov-04-19 04:10PM  
Oct-30-19 01:09PM  
Oct-28-19 04:05PM  
Oct-23-19 08:00AM  
Oct-18-19 10:23AM  
Oct-15-19 05:04PM  
Oct-14-19 08:00AM  
Oct-08-19 03:30PM  
Oct-02-19 04:05PM  
Sep-25-19 04:05PM  
Sep-04-19 04:05PM  
Aug-28-19 04:05PM  
Aug-23-19 12:06PM  
Aug-12-19 09:10PM  
Aug-06-19 08:24PM  
Aug-05-19 04:05PM  
Jul-29-19 04:05PM  
Jul-25-19 10:33AM  
Jul-17-19 08:00AM  
Jul-09-19 10:50AM  
Jul-08-19 09:41AM  
Jun-26-19 02:06PM  
Jun-06-19 08:05AM  
Jun-04-19 04:05PM  
May-22-19 01:33AM  
May-14-19 04:05PM  
May-09-19 10:23AM  
May-08-19 04:05PM  
May-07-19 12:51PM  
May-01-19 02:21PM  
Apr-24-19 04:05PM  
Apr-09-19 08:00AM  
Apr-08-19 04:05PM  
Apr-04-19 05:46PM  
Apr-02-19 04:05PM  
Apr-01-19 01:48PM  
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.